Sparteine

Summary

Sparteine (CHEMBL1908847) is an approved small molecule (ATC C01BA04); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01BA04
• Indications: 1 condition
• Chemistry: 234.38 Da · C15H26N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908847
Name	Sparteine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	644020
ChEBI	CHEBI:28827
ATC	C01BA04
Molecular formula	C15H26N2
Molecular weight	234.38
InChIKey	SLRCCWJSBJZJBV-ZQDZILKHSA-N

SMILES: C1CCN2C[C@@H]3C[C@H]([C@H]2C1)CN4[C@H]3CCCC4

IUPAC name: (1S,2R,9S,10S)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane

Also known as: Esparteina, Sparteine, sparteine, SID26754417, SID144203937, (+)-sparteine, SID170465740, SPARTEINE

Parent form; salt/anhydrous children: CHEMBL1908348, CHEMBL2165222, CHEMBL3276452, CHEMBL5316209

Patent coverage: 1,234 distinct patent families (3,282 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Menin/Histone-lysine N-methyltransferase MLL, Cytochrome P450 2D6.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 20 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).